PVTTF News Alert Pivotal Therapeutics (PVTTF) 0.0670 02/15/2015
Post# of 64074
Posted On: 02/15/2015 10:44:50 AM
Pivotal Therapeutics (PVTTF) 0.0670 $PVTTF
IIROC Trade Resumption - PVO
CNW Group - Tue Feb 10, 11:41AM CST
Trading resumes in:
Pivotal announces the issuance of two patents both related to the combination of VASCAZEN® with key Cholesterol Lowering Agents (Statins) and Cholesterol Absorption Inhibitors
PR Newswire - Tue Feb 10, 11:28AM CST
Pivotal Therapeutics Inc. (OTCQX
VTTF; CSE VO), ("Pivotal" or the "Company"
, a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease and overall health, announced today that the U.S. Patent and Trademark Office (USPTO) has issued Patent Number 8,951,514 titled "STATIN and Omega-3 Fatty Acids for Reduction of Apolipoprotein-B Levels" and Patent Number 8,952,000 titled "Cholesterol Absorption Inhibitor and Omega-3 Fatty Acids for the Reduction of Cholesterol and for the Prevention or Reduction of Cardiovascular, Cardiac and Vascular Events." Both of these patents cover VASCAZEN®'s formulation in conjunction with a Statin and Cholesterol Absorption Inhibitor respectively. These patents have terms that expire no earlier than 2032.
IIROC Trading Halt - PVO
CNW Group - Tue Feb 10, 11:24AM CST
The following issues have been halted by IIROC:
Pivotal Therapeutics Receives Final Approval for Phase IIa Clinical Trial With PVT-100
CNW Group - Tue Jan 27, 12:23PM CST
Pivotal Therapeutics Inc. (OTCQX VTTF; CSE VO), ("Pivotal" or the "Company" , a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease and overall health, announced today that it has received the final and unrestricted authorization from the Agence Nationale de la Sécurité du Médicament - French National Agency for Drug Safety to conduct a Phase IIa clinical trial with its PVT-100 drug candidate. PVT-100 uses VASCAZEN(®)'s proprietary formulation for the stabilization of vulnerable plaque in patients undergoing carotid endarterectomy, a surgical procedure to remove material accumulated in the arteries to reduce the risk of stroke.
Pivotal Therapeutics: Year in Review and CEO Update
CNW Group - Thu Jan 22, 2:38PM CST
Pivotal Therapeutics Inc. (OTCQX VTTF; CSE VO), ("Pivotal" or the "Company" , a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease and overall health is pleased to provide you with a summary of the Company's accomplishments in 2014 and its outlook for 2015 from the CEO, Mr. Eugene Bortoluzzi.
Pivotal Therapeutics announces payment of interest on outstanding convertible notes
PR Newswire - Mon Jan 05, 4:10PM CST
Pivotal Therapeutics Inc. (OTCQX VTTF; CSE VO), ("Pivotal" or the "Company" , a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease and overall health, announced that on December 17, 2014 it issued 772,237 common shares of the Corporation (the "Common Shares" . The Common Shares represented payment of interest for the period of September 5th, 2014 to December 4th, 2014 on its outstanding Convertible Notes that was due on or before January 1, 2015. Interest on the Notes, at the rate of 8% per annum, is payable quarterly in either cash or Common Shares, at the option of the Company. Common Shares issued in payment of interest are valued at the greater of CDN $0.20 per share and such price as may be allowed under the CSE Policy. The issued and outstanding number of shares now total 93,469,236.
VASCAZEN(R) POMEGA Phase IIa Trial Protocol Cleared Clinical Evaluation by French FDA
PR Newswire Europe - Wed Dec 17, 6:34AM CST
WOODBRIDGE, Ontario, December 17, 2014 /PRNewswire/ --
VASCAZEN® POMEGA Phase IIa trial protocol cleared clinical evaluation by French FDA
CNW Group - Wed Dec 17, 6:30AM CST
Pivotal Therapeutics Inc. (OTCQX VTTF; CSE VO), ("Pivotal" or the "Company" , a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease (CVD) and overall health, announced that on December 16, 2014 the French FDA in Paris (ANSM: Agence Nationale de la Sécurité du Médicament - French National Agency for Drug Safety) officially cleared the clinical evaluation part of the VASCAZEN(®) POMEGA Phase IIa trial protocol.
Pivotal Therapeutics Announces Third Quarter Accomplishments and Financial Results
CNW Group - Fri Nov 28, 4:22PM CST
Pivotal Therapeutics Inc. (OTCQX VTTF; CSE VO), ("Pivotal" or the "Company" , a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease (CVD) and overall health, announced its accomplishments and financial results for the three months ended September 30, 2014. All dollar amounts referenced herein are in Canadian dollars unless otherwise stated.
Pivotal Receives Notification of Allowance for U.S. Patent Related to Combination VASCAZEN(R) and Cholesterol Absorption Inhibitor
PR Newswire Europe - Wed Nov 26, 11:05AM CST
WOODBRIDGE, Ontario, October 8, 2014 /PRNewswire/ --
Pivotal Therapeutics Announces Notification of Patent Allowance for U.S. Application 13/584,480 Related to Combination Product of VASCAZEN(R) and Statin Therapy
PR Newswire Europe - Wed Nov 26, 10:06AM CST
WOODBRIDGE, Ontario, October 7, 2014 /PRNewswire/ --
Pivotal Therapeutics Announces Senior Management Change
CNW Group - Fri Nov 14, 2:15PM CST
Pivotal Therapeutics Inc. (OTCQX VTTF; CSE VO), ("Pivotal" or the "Company" , a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease and overall health, announced that Prakash Gowd has left as CFO to pursue new opportunities. "We would like to thank Prakash for his contributions and wish him well in his future endeavours," said Eugene Bortoluzzi, CEO, who has re-assumed the CFO role in addition to his CEO responsibilities.
Pivotal Receives Notification of Allowance for U.S. Patent Related to Combination VASCAZEN® and Cholesterol Absorption Inhibitor
CNW Group - Wed Oct 08, 11:44AM CDT
Pivotal Therapeutics Inc. (OTCQX VTTF; CSE VO), ("Pivotal" or the "Company" , a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease and overall health, announced that the United Stated Patent and Trademark Office (USPTO) has published notification of a Notice of Allowance for Pivotal's U.S. Patent Application Serial Number 13/584,403 titled "Cholesterol Absorption Inhibitor and Omega-3 Fatty Acids for the Reduction of Cholesterol and for the Prevention or Reduction of Cardiovascular, Cardiac and Vascular Events." This application includes claims intended to protect VASCAZEN(®) and its formulation in conjunction with at least one azetidinone cholesterol absorption inhibitor. This notice constitutes allowance of the patent and impending issuance. The issued patent would have a term that expires no earlier than in 2032.
IIROC Trade Resumption - PVO
CNW Group - Tue Feb 10, 11:41AM CST
Trading resumes in:
Pivotal announces the issuance of two patents both related to the combination of VASCAZEN® with key Cholesterol Lowering Agents (Statins) and Cholesterol Absorption Inhibitors
PR Newswire - Tue Feb 10, 11:28AM CST
Pivotal Therapeutics Inc. (OTCQX
VTTF; CSE VO), ("Pivotal" or the "Company" , a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease and overall health, announced today that the U.S. Patent and Trademark Office (USPTO) has issued Patent Number 8,951,514 titled "STATIN and Omega-3 Fatty Acids for Reduction of Apolipoprotein-B Levels" and Patent Number 8,952,000 titled "Cholesterol Absorption Inhibitor and Omega-3 Fatty Acids for the Reduction of Cholesterol and for the Prevention or Reduction of Cardiovascular, Cardiac and Vascular Events." Both of these patents cover VASCAZEN®'s formulation in conjunction with a Statin and Cholesterol Absorption Inhibitor respectively. These patents have terms that expire no earlier than 2032. IIROC Trading Halt - PVO
CNW Group - Tue Feb 10, 11:24AM CST
The following issues have been halted by IIROC:
Pivotal Therapeutics Receives Final Approval for Phase IIa Clinical Trial With PVT-100
CNW Group - Tue Jan 27, 12:23PM CST
Pivotal Therapeutics Inc. (OTCQX
VTTF; CSE VO), ("Pivotal" or the "Company" , a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease and overall health, announced today that it has received the final and unrestricted authorization from the Agence Nationale de la Sécurité du Médicament - French National Agency for Drug Safety to conduct a Phase IIa clinical trial with its PVT-100 drug candidate. PVT-100 uses VASCAZEN(®)'s proprietary formulation for the stabilization of vulnerable plaque in patients undergoing carotid endarterectomy, a surgical procedure to remove material accumulated in the arteries to reduce the risk of stroke. Pivotal Therapeutics: Year in Review and CEO Update
CNW Group - Thu Jan 22, 2:38PM CST
Pivotal Therapeutics Inc. (OTCQX
VTTF; CSE VO), ("Pivotal" or the "Company" , a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease and overall health is pleased to provide you with a summary of the Company's accomplishments in 2014 and its outlook for 2015 from the CEO, Mr. Eugene Bortoluzzi. Pivotal Therapeutics announces payment of interest on outstanding convertible notes
PR Newswire - Mon Jan 05, 4:10PM CST
Pivotal Therapeutics Inc. (OTCQX
VTTF; CSE VO), ("Pivotal" or the "Company" , a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease and overall health, announced that on December 17, 2014 it issued 772,237 common shares of the Corporation (the "Common Shares" . The Common Shares represented payment of interest for the period of September 5th, 2014 to December 4th, 2014 on its outstanding Convertible Notes that was due on or before January 1, 2015. Interest on the Notes, at the rate of 8% per annum, is payable quarterly in either cash or Common Shares, at the option of the Company. Common Shares issued in payment of interest are valued at the greater of CDN $0.20 per share and such price as may be allowed under the CSE Policy. The issued and outstanding number of shares now total 93,469,236. VASCAZEN(R) POMEGA Phase IIa Trial Protocol Cleared Clinical Evaluation by French FDA
PR Newswire Europe - Wed Dec 17, 6:34AM CST
WOODBRIDGE, Ontario, December 17, 2014 /PRNewswire/ --
VASCAZEN® POMEGA Phase IIa trial protocol cleared clinical evaluation by French FDA
CNW Group - Wed Dec 17, 6:30AM CST
Pivotal Therapeutics Inc. (OTCQX
VTTF; CSE VO), ("Pivotal" or the "Company" , a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease (CVD) and overall health, announced that on December 16, 2014 the French FDA in Paris (ANSM: Agence Nationale de la Sécurité du Médicament - French National Agency for Drug Safety) officially cleared the clinical evaluation part of the VASCAZEN(®) POMEGA Phase IIa trial protocol. Pivotal Therapeutics Announces Third Quarter Accomplishments and Financial Results
CNW Group - Fri Nov 28, 4:22PM CST
Pivotal Therapeutics Inc. (OTCQX
VTTF; CSE VO), ("Pivotal" or the "Company" , a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease (CVD) and overall health, announced its accomplishments and financial results for the three months ended September 30, 2014. All dollar amounts referenced herein are in Canadian dollars unless otherwise stated. Pivotal Receives Notification of Allowance for U.S. Patent Related to Combination VASCAZEN(R) and Cholesterol Absorption Inhibitor
PR Newswire Europe - Wed Nov 26, 11:05AM CST
WOODBRIDGE, Ontario, October 8, 2014 /PRNewswire/ --
Pivotal Therapeutics Announces Notification of Patent Allowance for U.S. Application 13/584,480 Related to Combination Product of VASCAZEN(R) and Statin Therapy
PR Newswire Europe - Wed Nov 26, 10:06AM CST
WOODBRIDGE, Ontario, October 7, 2014 /PRNewswire/ --
Pivotal Therapeutics Announces Senior Management Change
CNW Group - Fri Nov 14, 2:15PM CST
Pivotal Therapeutics Inc. (OTCQX
VTTF; CSE VO), ("Pivotal" or the "Company" , a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease and overall health, announced that Prakash Gowd has left as CFO to pursue new opportunities. "We would like to thank Prakash for his contributions and wish him well in his future endeavours," said Eugene Bortoluzzi, CEO, who has re-assumed the CFO role in addition to his CEO responsibilities. Pivotal Receives Notification of Allowance for U.S. Patent Related to Combination VASCAZEN® and Cholesterol Absorption Inhibitor
CNW Group - Wed Oct 08, 11:44AM CDT
Pivotal Therapeutics Inc. (OTCQX
VTTF; CSE VO), ("Pivotal" or the "Company" , a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease and overall health, announced that the United Stated Patent and Trademark Office (USPTO) has published notification of a Notice of Allowance for Pivotal's U.S. Patent Application Serial Number 13/584,403 titled "Cholesterol Absorption Inhibitor and Omega-3 Fatty Acids for the Reduction of Cholesterol and for the Prevention or Reduction of Cardiovascular, Cardiac and Vascular Events." This application includes claims intended to protect VASCAZEN(®) and its formulation in conjunction with at least one azetidinone cholesterol absorption inhibitor. This notice constitutes allowance of the patent and impending issuance. The issued patent would have a term that expires no earlier than in 2032. 
(0)
(0)Scroll down for more posts ▼